Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
Clinical Efficacy of Rifabutin in the Treatment of Serious and Life Threatening Infections Due to Mycobacterium Avium Complex, or Drug Resistant Mycobacterium Tuberculosis, or Other Drug Resistant Mycobacterium
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin.
Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.
Rifabutin dosage 150-300 mg daily( depending upon age, and clinical conditions) in NTM patients who fail treatment with rifampin.
Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
Inclusion Criteria: Adults age 18 and older with positive acid-fast bacilli smears and cultures for drug-resistant mycobacteria Exclusion Criteria: Children less than 18 years of age Pregnancy Low platelet count, except with very serious disease